COVID-19 Epidemiology and Vaccine Update

The current situation and how and what’s next?

Michael Lauzardo, MD MSc
Director, UF Health, Screen, Test, & Protect COVID-19 Program
Deputy Director, Emerging Pathogens Institute
Associate Professor, Division of Infectious Diseases and Global Medicine

December 17, 2020
University of Florida Faculty Senate Meeting
Perfect numbers, like perfect men, are very rare.

-Rene Descartes
Florida

COVID RISK LEVEL

Active or imminent outbreak
Florida is either actively experiencing an outbreak or is at extreme risk. COVID cases are exponentially growing and/or Florida's COVID preparedness is significantly below international standards.

DAILY NEW CASES
● 43.4 PER 100K
Dangerous number of new cases

INFECTION RATE
● 1.09
COVID is still spreading, but slowly

POSITIVE TEST RATE
● 10.6%
Indicates insufficient testing

ICU HEADROOM USED
● 48%
Can likely handle a new wave of COVID

TRACERS HIRED
● 6%
Too many cases and too few tracers hired

ALERT
The U.S. is in a third COVID wave. Exercise extra caution in order to reduce your risk of infection, to avoid infecting others, and to avoid overwhelming our healthcare system. Learn more.
Affiliate and Contact Tracing

UF-Affiliated Cases by Date of Onset of Symptoms, April 2020 - Present

Date of Onset of Symptoms

Number of Cases

7-Day Average
Vaccines
NO VACUNA
NO 5G
NO MASCARILLA
Background

- Pfizer and BioNTech
  - mRNA vaccine BNT162b2
  - Encodes the full-length spike protein

- Moderna
  - mRNA-1273 vaccine,
  - encodes the S-2P antigen, consisting of the SARS-CoV-2 glycoprotein with a transmembrane anchor and an intact S1–S2 cleavage site.

- AstraZeneca
  - Non-replicating viral vector vaccine AZD 1222

- Johnson&Johnson/Janssen
  - Non-replicating viral vector AD26.CoV2-S

- Sanofi
  - Protein Subunit

- Novavax
  - Protein Subunit
Latest Developments